Drug discovery grows, compliance work shrinks
FRONTEO, Inc. (TSE: 2158), which applies its KIBIT natural-language AI to drug discovery, legal technology and compliance, reported consolidated results for H1 FY3/2027, April 1 to September 30, 2026, on November 16, 2026 under Japanese GAAP. Life Science AI sales rose 40.3% to ¥384 million: AI drug discovery grew 38.3% to ¥257 million as co-creation projects with drug makers accumulated, including a new project with Astellas Pharma and a second one with Santen Pharmaceutical, and AI medical devices rose 44.6% to ¥127 million, helped by one-off development revenue. The segment's loss narrowed to ¥149 million despite hiring more researchers; FRONTEO opened its KIBIT AI Biology Lab in May and was supporting seven biotech ventures at the end of September.
Risk Management sales fell 24.2% to ¥1,539 million. Business-intelligence compliance work dropped 33.7% to ¥403 million after large clients, including manufacturers, cancelled; legal-tech AI fell 17.2% to ¥904 million as e-discovery declined, partly offset by more digital-forensics work for investigation committees; and economic-security work fell 40.6% to ¥139 million. The segment swung to a ¥114 million loss despite cost cuts including an exit from overseas operations. The DX segment, made up of subsidiary Arnetz, grew sales 32.7% to ¥1,429 million and segment profit 48.8% to ¥68 million.
Second-half recovery planned
The operating loss was ¥244 million, the ordinary loss ¥229 million and the net loss attributable to owners ¥186 million, or ¥4.77 per share. Total assets fell to ¥8,761 million and the equity ratio was 39.5%. FRONTEO says its plan was always weighted to the second half and kept its full-year forecast of net sales of ¥7,600 million, operating profit of ¥300 million, ordinary profit of ¥250 million and net profit of ¥150 million. It plans no dividend.
| Metric | H1 FY3/2027 | H1 FY3/2026 | Change |
|---|---|---|---|
| Net sales (¥ million) | 3,292 | 3,375 | −2.5% |
| Operating profit (¥ million) | −244 | −7 | loss widened |
| Ordinary profit (¥ million) | −229 | −25 | loss widened |
| Net profit attrib. to owners of parent (¥ million) | −186 | −72 | loss widened |
| EPS (¥) | −4.77 | −1.85 | loss widened |
| Life Science AI — revenue (¥ million) | 384 | 273 | +40.3% |
| Life Science AI — segment profit (¥ million) | −149 | −184 | loss narrowed |
| Risk Management — revenue (¥ million) | 1,539 | 2,031 | −24.2% |
| Risk Management — segment profit (¥ million) | −114 | 137 | profit to loss |
| DX — revenue (¥ million) | 1,429 | 1,077 | +32.7% |
| DX — segment profit (¥ million) | 68 | 46 | +48.8% |
| Total assets (¥ million) | 8,761 | 9,202 | −4.8% |
| Net assets (¥ million) | 3,645 | 3,844 | −5.2% |
| Equity ratio | 39.5% | 39.7% | −0.2 pt |
| FY3/2027 guidance — revenue (¥ million) | 7,600 | — | −0.6% |
| FY3/2027 guidance — operating profit (¥ million) | 300 | — | −59.4% |
| FY3/2027 guidance — ordinary profit (¥ million) | 250 | — | −63.0% |
| FY3/2027 guidance — net profit (¥ million) | 150 | — | −72.4% |
| Annual dividend per share (¥) | 0.00 | 0.00 | unchanged |
JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.